Kura Oncology (KURA) IPO Opens Flat

Today's IPO for Kura Oncology (NASDAQ: KURA) opened for trading at $8 after pricing 6,250,000 shares of common stock at a public offering price of $8.00 per share.

Citigroup and Leerink Partners are acting as joint book-running managers for the proposed offering. JMP Securities and Oppenheimer & Co. are acting as co-lead managers for the offering.

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in two Phase 2 clinical studies: the first in patients with locally advanced tumors that carry HRAS mutations and the second in patients with peripheral T-cell lymphoma. The company's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program.

You May Also Be Interested In

• Kura Oncology publishes ziftomenib preclinical data in Blood journal
• TCGX Acquisition Corp. raises $86.25M in Nasdaq IPO
• Nscale Touts $51 Billion In Contracts, Targets September US IPO - Bloomberg